Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: Results of a double-blind, randomized clinical trial

Journal of Interventional Cardiology

Volumn 22, Issue 4, 2009, Pages 368-377

  Nguyen, Thuy Anh ^a,b   Lordkipanidzé, Marie ^a,b   Diodati, Jean G ^a,b   Palisaitis, Donald A ^a,b   Schampaert, Erick ^a,b   Turgeon, Jacques ^a   Pharand, Chantal ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; PROTON PUMP INHIBITOR; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CELL ASSAY; CELL STIMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; ECCHYMOSIS; ELECTIVE SURGERY; FEMALE; HEMATURIA; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; CORONARY ARTERY DISEASE; HEART MUSCLE ISCHEMIA; MIDDLE AGED; STATISTICAL MODEL; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TIME FACTORS;

EID: 68849091527     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2009.00486.x     Document Type: Article

References (39)

1. Mak KH, Belli G, Ellis SG, et al. Subacute stent thrombosis: Evolving issues and current concepts. J Am Coll Cardiol 1996 27 : 494 503.
2. Schafer AI. Antiplatelet therapy. Am J Med 1996 101 : 199 209.
3. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 : 494 502.
4. Steinhubl SR, Berger PB, Mann JT, III., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002 288 : 2411 2420.
5. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005 45 : 1157 1164.
6. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003 59 : 295 302.
7. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004 109 : 3171 3175.
8. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006 27 : 2420 2425.
9. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: Insights into the STRATEGY Study. J Am Coll Cardiol 2006 48 : 2178 2185.
10. Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005 45 : 1392 1396.
11. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006 48 : 1742 1750.
12. Samara WM, Bliden KP, Tantry US, et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005 115 : 89 94.
13. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006 48 : 1339 1345.
14. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003 107 : 2908 2913.
15. Ford NF. Clopidogrel resistance: Pharmacokinetic or pharmacogenetic? J Clin Pharmacol 2009 49 : 506 512.
16. Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: Insights from the PCI-CURE study. Eur Heart J 2009 30 : 900 907.
17. King SB, III., Smith SC, Jr., Hirshfeld JW, Jr., et al. 2007 focused update of the ACC-AHA-SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology-American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008 51 : 172 209.
18. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005 26 : 804 847.
19. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988 11 : 1 11.
20. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008 29 : 992 1000.
21. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004 25 : 1903 1910.
22. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007 115 : 708 716.
23. von Beckerath N, Kastrati A, Wieczorek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007 28 : 1814 1819.
24. Angiolillo DJ, Bernardo E, Palazuelos J, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost 2008 99 : 161 168.
25. Szuk T, Gyongyosi M, Homorodi N, et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 2007 153 : 289 295.
26. Harrison P, Mackie I, Mathur A, et al. Platelet hyper-function in acute coronary syndromes. Blood Coagul Fibrinolysis 2005 16 : 557 562.
27. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: Choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 2005 112 : 2946 2950.
28. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial. J Am Coll Cardiol 2006 48 : 931 938.
29. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008 121 : 463 468.
30. Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004 92 : 311 316.
31. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007 49 : 2312 2317.
32. Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006 47 : 939 943.
33. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006 80 : 486 501.
34. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008 51 : 1404 1411.
35. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006 4 : 542 549.
36. de Gaetano G, Cerletti C. Platelet function, antiplatelet therapy and clinical outcomes: To test or not to test? J Thromb Haemost 2007 5 : 1835 1838.
37. Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007 5 : 1839 1847.
38. Lordkipanidzé M, Pharand C, Nguyen TA, et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008 29 : 2877 2885.
39. Michelson AD, Frelinger AL, III., Furman MI. Current options in platelet function testing. Am J Cardiol 2006 98 : S4 S10.